IL6 and prostate carcinoma: (40) demonstrated that the high expression of IL-6 produced by stromal cells (α-SMA+ cells), in prostate cancer tissue, is correlated with an induction of tolerogenic DCs phenotype, characterized by cells expressing high surface levels of CD14 and PD-L1.